Skip to main content
Premium Trial:

Request an Annual Quote

If You Can't Beat 'Em...

The Wall Street Journal reports that Merck is creating a unit to make generic versions of biotech drugs. The story quotes CEO Richard Clark as saying, "We believe we can become the leading provider of high-quality, competitively priced follow-on biologics." One hurdle will be the lack of an FDA approval path for these biosimilars, but the article says that the incoming Obama administration has "raised expectations that Congress will clear the regulatory path as soon as next year."

 

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.